- Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
- Avalo Reports 2023 Financial Results and Provides Business Updates
- Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
- Avalo Therapeutics Announces 1-for-240 Reverse Stock Split
- Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split
- Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates
- Avalo Completes Divestiture of AVTX-800 Series
- Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation
- Avalo Enters into Agreement to Divest AVTX-800 Series
- Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference
More ▼
Key statistics
On Friday, Avalo Therapeutics Inc (AVTX:NAQ) closed at 14.36, 263.54% above the 52 week low of 3.95 set on Jan 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 15.58 |
---|---|
High | 16.00 |
Low | 13.15 |
Bid | 13.80 |
Offer | 16.17 |
Previous close | 15.39 |
Average volume | 76.36k |
---|---|
Shares outstanding | 1.03m |
Free float | 974.82k |
P/E (TTM) | -- |
Market cap | 14.85m USD |
EPS (TTM) | -381.36 USD |
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼